TWI756495B - 用以治療或預防與骨量減少相關疾病、改善骨骼結構及提高骨骼生物力學強度之方法 - Google Patents

用以治療或預防與骨量減少相關疾病、改善骨骼結構及提高骨骼生物力學強度之方法 Download PDF

Info

Publication number
TWI756495B
TWI756495B TW107141816A TW107141816A TWI756495B TW I756495 B TWI756495 B TW I756495B TW 107141816 A TW107141816 A TW 107141816A TW 107141816 A TW107141816 A TW 107141816A TW I756495 B TWI756495 B TW I756495B
Authority
TW
Taiwan
Prior art keywords
bone
day
composition
genistein
effective amount
Prior art date
Application number
TW107141816A
Other languages
English (en)
Chinese (zh)
Other versions
TW201924691A (zh
Inventor
王上達
許宸
蘇南維
Original Assignee
休斯生物科技股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 休斯生物科技股份有限公司 filed Critical 休斯生物科技股份有限公司
Publication of TW201924691A publication Critical patent/TW201924691A/zh
Application granted granted Critical
Publication of TWI756495B publication Critical patent/TWI756495B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
TW107141816A 2017-12-07 2018-11-23 用以治療或預防與骨量減少相關疾病、改善骨骼結構及提高骨骼生物力學強度之方法 TWI756495B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595697P 2017-12-07 2017-12-07
US62/595,697 2017-12-07

Publications (2)

Publication Number Publication Date
TW201924691A TW201924691A (zh) 2019-07-01
TWI756495B true TWI756495B (zh) 2022-03-01

Family

ID=64559585

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107141816A TWI756495B (zh) 2017-12-07 2018-11-23 用以治療或預防與骨量減少相關疾病、改善骨骼結構及提高骨骼生物力學強度之方法

Country Status (6)

Country Link
US (1) US10881634B2 (https=)
EP (1) EP3494973B1 (https=)
JP (1) JP7029172B2 (https=)
KR (1) KR102376603B1 (https=)
CN (1) CN109939118A (https=)
TW (1) TWI756495B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025117337A1 (en) * 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives
CN118359663B (zh) * 2024-04-26 2024-12-13 西安交通大学医学院第一附属医院 线粒体靶向染料木素衍生物及其在制备抗心肌缺血再灌注损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111466A1 (en) * 2000-12-15 2002-08-15 Hendler Sheldon S. Isoflavone derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4435199A (en) * 1998-06-12 1999-12-30 Vyrex Corporation Isoflavone derivatives
JP2007511542A (ja) * 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
TR201004464A2 (tr) * 2010-06-03 2012-11-21 B�Lg�� Mahmut Kemik erimesi için formülasyon.
US8900635B2 (en) * 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
CN102351828A (zh) * 2011-08-16 2012-02-15 李荣立 一种提取金雀异黄素的新工艺
CN102488210B (zh) * 2011-12-27 2013-06-19 西南大学 染料木素水凝胶的复合物及其制备方法
CN105381470B (zh) * 2015-11-27 2018-11-02 广东医科大学 一种改性染料木素及其应用
TWI670374B (zh) * 2016-04-25 2019-09-01 國立臺灣大學 具有苯並吡喃酮類磷酸酯合成酶活性之多肽、包含編碼該多肽之核酸序列之微生物及苯並吡喃酮類磷酸酯衍生物之製備方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020111466A1 (en) * 2000-12-15 2002-08-15 Hendler Sheldon S. Isoflavone derivatives

Also Published As

Publication number Publication date
EP3494973A1 (en) 2019-06-12
JP2019099579A (ja) 2019-06-24
TW201924691A (zh) 2019-07-01
EP3494973B1 (en) 2021-07-28
CN109939118A (zh) 2019-06-28
US10881634B2 (en) 2021-01-05
KR102376603B1 (ko) 2022-03-18
US20190175545A1 (en) 2019-06-13
KR20190067695A (ko) 2019-06-17
JP7029172B2 (ja) 2022-03-03

Similar Documents

Publication Publication Date Title
CN1193751C (zh) 一种含有五羟黄酮衍生物活性成分的骨质疏松症治疗剂
CN103736074B (zh) 一种增加骨密度保健胶囊及其制备方法
JP2012511547A (ja) イソフラボン組成物
CN101791341B (zh) 一种中药组合物在制备治疗骨质疏松症药物中的应用
CN104068306B (zh) 一种增加骨密度的保健食品及其制备方法
KR100961291B1 (ko) 골다공증 치료용 조성물의 제조에 사용되는 글루타메이트,글루타메이트 유도체 또는 대사산물, 글루타메이트 유사체또는 이들의 혼합물의 용도
TWI756495B (zh) 用以治療或預防與骨量減少相關疾病、改善骨骼結構及提高骨骼生物力學強度之方法
Devareddy et al. The effects of fructo-oligosaccharides in combination with soy protein on bone in osteopenic ovariectomized rats
CN103584106A (zh) 一种具有增加骨密度功能的组合物
US11116781B2 (en) Composition, containing Loganin or a derivative thereof as an active ingredient for preventing, remedying, or treating female climacteric syndrome
Lee et al. Evaluation of effectiveness and safety of natural plants extract (Estromon®) on perimenopausal women for 1 year
WO2018107324A1 (zh) 一种降低了高钙血风险的补钙组合物及其应用
JP3604710B2 (ja) 骨粗鬆症予防及び治療剤
WO2006135121A1 (en) Bone disease drug composition using herb medicines
CN100348207C (zh) 沙棘果油和果渣油在制备防治骨质疏松症药物中的应用
Williams et al. Bisphosphonates and nephrocalcinosis in a rabbit leg lengthening model: a histological and therapeutic comparison
CN115400177A (zh) 一种预防或治疗原发性骨质疏松症药物组合物及其制备方法
CN115251339B (zh) 一种通过调节肠道菌群增加骨密度的功能食品组合物及其制备方法
JP5627081B2 (ja) 骨粗鬆症予防・治療剤及び健康食品
Fan et al. Protective Effect of Panax ginseng on osteoporosis in Ovariectomized Female Guinea-pigs
WO2013174812A1 (en) Fructus ligustri lucidi for bones in young subjects
CN115702903A (zh) 水晶兰苷在促进骨折愈合中的应用
KR101401002B1 (ko) Ｈｓ1792 또는 이의 약학적으로 허용되는 염을 포함하는 골량 저하 관련 질환의 예방 또는 치료용 약학 조성물 및 건강기능식품
DOWNEY Thwart POST-MEAL Bloating and Indigestion
TWI474826B (zh) 治療及／或預防骨質疏鬆症之組合物